Literature DB >> 10896900

The science, economics, and effectiveness of combination therapy for hepatitis C.

G Dusheiko1, E Barnes, G Webster, S Whalley.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10896900      PMCID： PMC1728019          DOI： 10.1136/gut.47.2.159

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  17 in total

1.  An infectious molecular clone of a Japanese genotype 1b hepatitis C virus.

Authors:  M R Beard; G Abell; M Honda; A Carroll; M Gartland; B Clarke; K Suzuki; R Lanford; D V Sangar; S M Lemon
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

2.  In pursuit of quality: the National Institute for Clinical Excellence.

Authors:  M Rawlins
Journal:  Lancet       Date:  1999-03-27       Impact factor: 79.321

3.  Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

Authors:  S Khakoo; P Glue; L Grellier; B Wells; A Bell; C Dash; I Murray-Lyon; D Lypnyj; B Flannery; K Walters; G M Dusheiko
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

4.  Making sense of hepatitis C.

Authors:  K Hurtado
Journal:  Lancet       Date:  1999-02-06       Impact factor: 79.321

5.  Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation.

Authors:  S C Darby; D W Ewart; P L Giangrande; R J Spooner; C R Rizza; G M Dusheiko; C A Lee; C A Ludlam; F E Preston
Journal:  Lancet       Date:  1997-11-15       Impact factor: 79.321

6.  Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.

Authors:  I Cacciola; T Pollicino; G Squadrito; G Cerenzia; M E Orlando; G Raimondo
Journal:  N Engl J Med       Date:  1999-07-01       Impact factor: 91.245

Review 7.  Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C.

Authors:  G L Davis
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  Rising incidence of hepatocellular carcinoma in the United States.

Authors:  H B El-Serag; A C Mason
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

9.  Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

Authors:  T Poynard; P Bedossa; P Opolon
Journal:  Lancet       Date:  1997-03-22       Impact factor: 79.321

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245
View more
  1 in total

1.  Interferon-beta plus ribavirin for patients with hepatitis C virus genotype 1: a randomised pilot trial.

Authors:  M Enomoto; A Tamori; N Kawada; H Jomura; S Nishiguchi; T Saibara; S Onishi; S Mochida; K Fujiwara
Journal:  Gut       Date:  2006-01       Impact factor: 23.059
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.